Troxipide

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Troxipide 是一种新型全身性非抗分泌性胃细胞保护剂，具有抗溃疡、抗炎和粘液分泌特性，与胃或十二指肠 pH 值无关。

Troxipide is a novel systemic non-antisecretory gastric cytoprotective agent with anti-ulcer, anti-inflammatory and mucus secreting properties irrespective of pH of stomach or duodenum.(In Vitro):Troxipide exerts inhibitory, therapeutic and preventive effects to specifically those in the stomach by enhancing gastric mucosal blood flow and gastric mucosal defense factors and promoting tissue repair, blood circulation, metabolism and GU repair.(In Vivo):Troxipide (40 mg/kg; iv) significantly alleviates gastric ulcer (GU).Troxipide (40 mg/kg; iv) has a T1/2 of 210 min and 428.73 min for NCG and GUG rat, respectively.

Troxipide exerts inhibitory, therapeutic and preventive effects to specifically those in the stomach by enhancing gastric mucosal blood flow and gastric mucosal defense factors and promoting tissue repair, blood circulation, metabolism and GU repair.

Troxipide (40 mg/kg; iv) significantly alleviates gastric ulcer (GU). Troxipide (40 mg/kg; iv) has a T1/2 of 210 min and 428.73 min for NCG and GUG rat, respectively. Animal Model:Normal control group (NCG) and gastric ulcer group (GUG) rat (5% acetic acid 10 mL/kg/day) Dosage:10, 20, 40, 60 mg/kg Administration:Oral; daily; 2 weeks Result:The levels of these cytokines (IL-17, IL-6, TNF-α, IFN-γ and AP-1) were significantly reduced, suggesting that GU was significantly alleviated.Animal Model:NCG and GUG rat Dosage:40 mg/kg for iv Administration:IV Result:Had a T1/2 of 210 min and 428.73 min for NCG and GUG rat, respectively.

BRN0493078 | Troxipide | Troxipida | Troxipidum

Others

Other Targets

Others

Inflammation/Immunology

——

30751-05-4

294.35

C15H22N2O4

>98% (HPLC)

Ethanol: 3 mg/mL (10.19 mM); DMSO: 18 mg/mL (61.15 mM)

O=C(NC1CNCCC1)C2=CC(OC)=C(OC)C(OC)=C2

3,4,5-trimethoxy-N-(piperidin-3-yl)benzamide

(-20℃)

With Ice Pack

≥ 2 years